Literature DB >> 3142344

Iontophoretic application of tobramycin to uninfected and Pseudomonas aeruginosa-infected rabbit corneas.

J A Hobden1, D S Rootman, R J O'Callaghan, J M Hill.   

Abstract

Pseudomonas aeruginosa keratitis was induced in rabbits to study the effects of corneal infection on the delivery of tobramycin by iontophoresis. Some rabbits were treated by use of an eye cup with no current as a control for iontophoresis, and others were treated with fortified drops (1.36%) delivered topically for comparison with results of earlier studies. One hour after treatment with tobramycin, the concentration of drug in the infected corneas was compared with that achieved in mock-infected and uninfected eyes. Iontophoresis of 25 mg of tobramycin per ml at 0.8 mA for 10 min delivered significantly more drug (P = 0.0001) to corneal tissue than did drops or use of an eye cup without current in P. aeruginosa-infected eyes mock-infected eyes, or uninfected eyes. Tobramycin concentrations in the infected corneas (605.9 micrograms/g) were not significantly different (P = 0.815) from the concentrations in mock-infected eyes (641.4 micrograms/g), but were lower (P = 0.007) than those obtained by iontophoresis in uninfected corneas (853.6 micrograms/g). Use of an eye cup without current delivered tobramycin equally to infected, mock-infected, and normal eyes, i.e., 176.5, 171.0, and 163.1 micrograms/g, respectively (P greater than 0.709). Tobramycin delivered by use of fortified drops delivered topically was detectable in mock-infected corneas (20 micrograms/g) and P. aeruginosa-infected corneas (6.0 micrograms/g). These results suggest that iontophoresis has value as an ocular drug delivery system and that an eye cup could also be useful in a therapeutic regimen for ocular infections.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3142344      PMCID: PMC172328          DOI: 10.1128/AAC.32.7.978

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Ocular penetration of topically applied gentamicin.

Authors:  B Ellerhost; B Golden; N Jarudi
Journal:  Arch Ophthalmol       Date:  1975-05

2.  Comparison of therapeutic routes in experimental Pseudomonas keratitis.

Authors:  S D Davis; L D Sarff; R A Hyndiuk
Journal:  Am J Ophthalmol       Date:  1979-05       Impact factor: 5.258

3.  Regional differences in ocular concentration of gentamicin after subconjunctival and retrobulbar injection in the rabbit.

Authors:  M Barza; A Kane; J L Baum
Journal:  Am J Ophthalmol       Date:  1977-03       Impact factor: 5.258

Review 4.  Experimental Pseudomonas keratitis.

Authors:  R A Hyndiuk
Journal:  Trans Am Ophthalmol Soc       Date:  1981

Review 5.  Drug delivery to the eye.

Authors:  G C Chiou; K Watanabe
Journal:  Pharmacol Ther       Date:  1982       Impact factor: 12.310

Review 6.  Permeability of the cornea to topically applied drugs.

Authors:  H Benson
Journal:  Arch Ophthalmol       Date:  1974-04

7.  Gentamicin penetration in the aqueous humor of eyes with corneal ulcers.

Authors:  S H Sloan; T H Pettit; K D Litwack
Journal:  Am J Ophthalmol       Date:  1972-05       Impact factor: 5.258

Review 8.  Acute bacterial infection of the eye: bacterial keratitis and endophthalmitis.

Authors:  L A Wilson
Journal:  Trans Ophthalmol Soc U K       Date:  1986

9.  Topical vs subconjunctival treatment of bacterial corneal ulcers.

Authors:  J Baum; M Barza
Journal:  Ophthalmology       Date:  1983-02       Impact factor: 12.079

10.  Route of antibiotic administration in bacterial keratitis.

Authors:  H M Leibowitz; W J Ryan; A Kupferman
Journal:  Arch Ophthalmol       Date:  1981-08
View more
  1 in total

Review 1.  Pharmacokinetic considerations in the treatment of bacterial keratitis.

Authors:  M C Callegan; R J O'Callaghan; J M Hill
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.